Change in plasma drug activity measured at the time of estimated peak concentration (2hr) after 2 and 4 weeks of treatment.

<p>TDA = Tuberculosis drug activity, where values greater than 1.0 indicate <i>in vitro</i> killing of a patient’s plasma against their own <i>M</i>. <i>tuberculosis</i> isolate. p = 0.005 by paired sample t-test.</p

Sputum culture positive by week in MGIT system, N = 25.

<p>All patients (100%) culture positive from pretreatment sputum specimen.</p

Clinical characteristics, patients treated for pulmonary multidrug-resistant tuberculosis (MDR-TB), N = 25.

<p>^aAt MDR-TB treatment initiation.</p><p>Clinical characteristics, patients treated for pulmonary multidrug-resistant tuberculosis (MDR-TB), N = 25.</p

Predictors of favorable interim treatment outcome using exact logistic regression.

<p>^aGreater change in time-to-positivity (TTP) reflects greater decrement in sputum bacterial burden.</p><p>Predictors of favorable interim treatment outcome using exact logistic regression.</p

Prevalence of medication related symptoms.

<p>The prevalence of medication related symptoms during the inpatient intensive phase occurring at least once in an individual patient, as determined by percentage of total patients (N = 61).</p

Comparison of patients that completed intensive phase of MDR-TB therapy to those that died.

*<p>Excludes 3 patients that defaulted.</p>†<p>Excludes 8 patients for whom follow-up sputum culture results unavailable.</p><p>N/a =  not applicable.</p

Distribution of the time to sputum culture conversion.

<p>Legend: Sputum was collected for culture prior to treatment initiation and monthly thereafter. Culture conversion was defined as the first of two consecutive months of negative cultures. Eight subjects were excluded as regular follow-up culture results were unavailable.</p

Patients referred to KNTH for MDR-TB treatment.

<p>KNTH =  Kibong’oto National TB Hospital, Tanzania. MDR-TB =  multidrug-resistant tuberculosis. All patients had pulmonary TB.</p

Baseline characteristics for those initiating MDR-TB treatment (N = 61).

<p>N/A =  not applicable.</p>*<p>6 (67%) of HIV positive patients were on antiretroviral therapy prior to referral for MDR-TB treatment.</p>†<p>Forty-eight baseline chest radiographs were available for analysis.</p